Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Depreciation and Depletion (2017 - 2025)

Historic Depreciation and Depletion for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $100000.0.

  • Aclaris Therapeutics' Depreciation and Depletion fell 5000.0% to $100000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $400000.0, marking a year-over-year decrease of 5000.0%. This contributed to the annual value of $700000.0 for FY2024, which is 1250.0% down from last year.
  • As of Q3 2025, Aclaris Therapeutics' Depreciation and Depletion stood at $100000.0, which was down 5000.0% from $100000.0 recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Depreciation and Depletion ranged from a high of $200000.0 in Q1 2021 and a low of $100000.0 during Q4 2022
  • For the 5-year period, Aclaris Therapeutics' Depreciation and Depletion averaged around $173684.2, with its median value being $200000.0 (2021).
  • Per our database at Business Quant, Aclaris Therapeutics' Depreciation and Depletion tumbled by 5000.0% in 2022 and then soared by 10000.0% in 2023.
  • Aclaris Therapeutics' Depreciation and Depletion (Quarter) stood at $200000.0 in 2021, then crashed by 50.0% to $100000.0 in 2022, then soared by 100.0% to $200000.0 in 2023, then crashed by 50.0% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025.
  • Its last three reported values are $100000.0 in Q3 2025, $100000.0 for Q2 2025, and $100000.0 during Q1 2025.